Heat Biologics, Inc. (NASDAQ:HTBX) – Stock analysts at Griffin Securities issued their Q3 2017 EPS estimates for shares of Heat Biologics in a research report issued on Tuesday. Griffin Securities analyst K. Markey expects that the biopharmaceutical company will post earnings per share of ($0.09) for the quarter. Griffin Securities has a “Buy” rating and a $2.25 price objective on the stock. Griffin Securities also issued estimates for Heat Biologics’ Q4 2017 earnings at ($0.07) EPS, FY2017 earnings at ($0.35) EPS, Q1 2018 earnings at ($0.07) EPS, Q2 2018 earnings at ($0.07) EPS, Q3 2018 earnings at ($0.05) EPS, Q4 2018 earnings at ($0.05) EPS, FY2018 earnings at ($0.23) EPS, FY2019 earnings at ($0.19) EPS, FY2020 earnings at ($0.25) EPS and FY2021 earnings at $0.17 EPS.
A number of other research analysts also recently issued reports on the stock. Zacks Investment Research raised shares of Heat Biologics from a “hold” rating to a “buy” rating and set a $0.75 price objective on the stock in a research report on Thursday, May 25th. ValuEngine downgraded shares of Heat Biologics from a “sell” rating to a “strong sell” rating in a research report on Thursday, July 13th. Finally, Noble Financial reaffirmed a “buy” rating on shares of Heat Biologics in a research report on Tuesday, July 4th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $1.67.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.chaffeybreeze.com/2017/09/17/heat-biologics-inc-htbx-forecasted-to-earn-q3-2017-earnings-of-0-09-per-share.html.
Heat Biologics (HTBX) opened at 0.6191 on Friday. Heat Biologics has a 52 week low of $0.46 and a 52 week high of $3.35. The stock has a 50 day moving average of $0.53 and a 200 day moving average of $0.68. The company’s market cap is $22.16 million.
Hedge funds have recently added to or reduced their stakes in the stock. KCG Holdings Inc. boosted its stake in Heat Biologics by 35.3% in the 1st quarter. KCG Holdings Inc. now owns 175,769 shares of the biopharmaceutical company’s stock worth $156,000 after purchasing an additional 45,831 shares in the last quarter. Vanguard Group Inc. boosted its stake in Heat Biologics by 11.9% in the 2nd quarter. Vanguard Group Inc. now owns 661,388 shares of the biopharmaceutical company’s stock worth $403,000 after purchasing an additional 70,290 shares in the last quarter. Finally, Sabby Management LLC acquired a new stake in Heat Biologics in the 1st quarter worth approximately $2,176,000. Institutional investors own 8.74% of the company’s stock.
About Heat Biologics
Heat Biologics, Inc is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT).
Receive News & Ratings for Heat Biologics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.